Sulfide:quinone oxidoreductase ameliorates neurodegeneration in a murine model of Parkinson’s disease

Fumiaki Nagashima a,b, Yusuke Miyazaki a,b, Eiki Kanemaru a,b, Mariko Ezaka a,b, Hiroaki Hara a,b, Kei Sugiuira a,b, Sophie L. Boerboom a,b, Katrina F. Ostrom a,b, Wanlin Jiang b,c, Donald B. Bloch a,b,c, Fumito Ichinose a,b,c, Eizo Marutani a,b,c,1

a Anesthesia Center for Critical Care Research of the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, MA, USA
b Harvard Medical School, Boston, MA, USA
c Division of Cardiology, Department of Medicine, Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
d Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

ARTICLE INFO

Keywords:
Parkinson’s disease
Sulfide catabolism
sulfide:quinone oxidoreductase
Persulfide
Polysulfide

Innovation

Parkinson’s Disease (PD) is the second most common neurodegenerative disease in humans. We used a mouse model of PD to investigate the effects of upregulating sulfide:quinone oxidoreductase (SQOR) in the brain. Increasing the level of SQOR in the brain, either using sulfide preconditioning (SPC) by intermittent inhalation of H2S or by adenovirus-associated virus (AAV)-mediated gene transfer, inhibited neurodegeneration and improved the movement disorder in PD mice. Furthermore, administration of polysulfide, a product of oxidation of H2S mediated by SQOR, mitigated neurodegeneration in this mouse model. The results of this study suggest that increased sulfide catabolism by SQOR may ameliorate the pathogenesis of PD. We anticipate that the availability of stable polysulfide compounds will accelerate the clinical translation of these results into innovative therapies for PD.

1. Introduction

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases in humans, second only to Alzheimer’s disease [1]. PD is characterized by the selective loss of dopaminergic neurons in the substantia nigra and deficiency of dopamine in the striatum [2]. Although the pathogenesis of PD is incompletely understood, increased oxidative stress [3], inhibition of complex I of the mitochondrial electron transport chain (ETC) [4,5], and aggregation of α-synuclein [6–8] are thought to have key roles in disease progression. Despite intensive research, currently there is no cure for PD.

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that inhibits mitochondrial ETC complex I. Following systemic administration, MPTP crosses the blood brain barrier and is converted (in astrocytes) to 1-methyl-4-phenylpyridinium ion (MPP+) by monoamine oxidase-B [9–11]. MPP+ binds to dopamine transporters on dopaminergic neurons with high affinity, facilitating cellular uptake and resulting in inhibition of ETC complex I, impairment of ATP production and increased oxidative stress and cell death [12–15]. The selective degeneration of dopaminergic neurons induced by MPTP partially reproduces the pathologic and phenotypic features of PD in both humans [16] and rodents [17]. Administration of MPTP to mice is therefore a frequently used model of human PD.

Hydrogen sulfide (H2S), a colorless gas with a characteristic rotten-egg odor, is found in various natural and industrial products [18]. In human blood, sulfide exists as H2S (20%) and HS− (80%) [19]. In mammalian cells, sulfides or closely related reactive sulfur species such...
as persulfides (RSSH) and polysulfides (RS_nH) are generated by enzymes that include cystathionine β-synthase (CBS), cystathionine γ-lyase (CSE), and 3-mercaptoppyruvate sulfurtransferase (3-MST) [20–22]. Sulfides are catabolized in mitochondria by sulfide oxidation enzymes. SQOR catalyzes the first step in H_2S oxidation, converting sulfide to persulfide [23]. Sulfane sulfur, a sulfur atom with 6 valence electrons and no charge, is a component of persulfide and polysulfide. Recent studies suggest that sulfane sulfur-containing molecules, such as persulfide and polysulfide, may protect against neurodegenerative diseases such as PD [24,25]. These molecules may inhibit oxidation of tissues or may facilitate mitochondrial bioenergetics [22,26,27]. Persulfide is further oxidized to thiosulfate, sulfite, and sulfate by persulfide dioxygenases (PDO or ETHE1), thiosulfate sulfurtransferase (TST), and sulfite oxidase (SUOX). The sulfane sulfur of persulfides including GSSH and CysSSH can be transferred to disulfide molecules such as GSSG and CysSSCys to generate various polysulfides (including GSSSG and CysSSSCys) in non-enzymatic reactions [26]. H_2S can also be generated from persulfide/polysulfide via enzymatic reactions or non-enzymatic reactions [28,29]. This complicated diversity of potential sulfur reactions has hindered our understanding of the protective roles of sulfide catabolism in human diseases.

Previously, we reported that chronic, intermittent H_2S inhalation protects mice from neurodegeneration and the movement disorder seen in the MPTP-induced mouse model of PD [30]. We showed that the neuroprotective effects of H_2S inhalation were associated with upregulation of nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent antioxidant and detoxification proteins in the brain. The precise mechanisms by which H_2S inhalation provided neuroprotection remained incompletely understood. In the previous study, H_2S inhalation began at the same time as MPTP administration, making it difficult to separate the effects of H_2S inhalation from those of MPTP. More recently, we reported that chronic intermittent H_2S inhalation markedly upregulated SQOR levels in the brain of mice [31]. Upregulated SQOR enabled mice to survive in severe hypoxia and mitigated ischemic brain injury, whereas depletion of brain SQOR increased the sensitivity of mice to oxygen deprivation. Under physiological conditions, H_2S oxidation by SQOR donates electrons to mitochondrial ETC complex III via coenzyme Q (CoQ), thereby potentially promoting ATP synthesis [32–34].
addition, SQOR converts \( \text{H}_2\text{S} \) to persulfide, a potent antioxidant [26, 35–37]. Furthermore, SQOR deficiency was recently reported to cause a Leigh syndrome-like disease, characterized by encephalopathy and the presence of brain lesions in the basal ganglia and cortex [38]. These observations suggest that sulfide oxidation by SQOR has a critical role in cerebral energy homeostasis under normal conditions, as well as during oxidative stress. However, the role of sulfide oxidation in the pathogenesis of PD is largely unknown.

The objective of the current study was to investigate the effects of sulfide preconditioning on the pathogenesis of PD in the MPTP-induced mouse model. To elucidate the mechanisms responsible for the beneficial effects of \( \text{H}_2\text{S} \) inhalation in PD, we examined the effects of chronic intermittent \( \text{H}_2\text{S} \) inhalation before MPTP, so that effects of SPC could be distinguished from those of MPTP. We hypothesized that upregulation of SQOR by SPC would mitigate neurodegeneration and the movement disorder that occur in the PD mouse model. We report that SQOR upregulation, either induced by SPC or AAV-mediated gene transfer, prevented MPTP-induced degeneration of dopaminergic neurons and movement disorder in mice. We further showed that administration of polysulfide, an oxidative product of sulfide catalyzed by SQOR, attenuated MPTP-induced neurodegeneration.

2. Results

2.1. Sulfide pre-conditioning protected mice from the movement disorder induced by MPTP

To investigate the effects of SPC on MPTP-induced neurodegeneration and movement disorder, mice were randomized into three groups: 1) mice breathing air for 5 days followed by saline administration on day 5 (Air + saline); 2) mice breathing air for 5 days followed by MPTP administration on day 5 (Air + MPTP); and 3) mice intermittently breathing \( \text{H}_2\text{S} \) at 80 ppm mixed in air for 4 h daily for 5 consecutive days followed by MPTP administration on day 5 (SPC + MPTP) (Fig. 1). An investigator, who was blinded to the mouse treatment group, assessed the levels of anxiety and motor function 7 days after administration of saline or MPTP, using the open-field- and rotarod tests, respectively. The open-field test quantifies murine anxiety by measuring the amount of time that mice spend in the central area of an "open field" and the distance that mice move from the central area [39]. Increased time in the central area and decreased movement from the central area are both measures of increased anxiety. Compared to mice that were not preconditioned with \( \text{H}_2\text{S} \), mice that were treated with \( \text{H}_2\text{S} \) demonstrated decreased anxiety after MPTP administration. The rotarod performance...
test measures the amount of time that a mouse is able to stay on a rotating rod and is a measure of coordination, grip strength and motor coordination [40]. Compared to mice that did not receive H₂S, mice that were pre-treated with H₂S and then administered MPTP retained the ability to balance on the rotarod (Fig. 2, A-C). These observations suggest that SPC protected mice from anxiety and the movement disorder induced by MPTP.

2.2. Sulfide pre-conditioning prevented MPTP-induced degeneration of dopaminergic neurons

The degree of neurodegeneration induced by MPTP can be assessed by measuring the decrease in levels of tyrosine hydroxylase in the substantia nigra and striatum (the nigrostriatal region). Compared to untreated (control) mice, administration of MPTP decreased the level of tyrosine hydroxylase in the nigrostriatal region, as assessed by immunoblot. In contrast, preconditioning with H₂S prevented the MPTP-induced decrease in tyrosine hydroxylase. (Fig. 3). These results show that SPC prevents MPTP-induced degeneration of dopaminergic neurons in the substantia nigra and striatum.

2.3. Sulfide pre-conditioning upregulated SQOR in substantia nigra and striatum

To explore the mechanisms responsible for the beneficial effects of SPC, we examined levels of SQOR in substantia nigra and striatum in mice with or without SPC. Immunoblots revealed that SPC significantly increased levels of SQOR in the nigrostriatal region (Fig. 4). In contrast, the levels of other enzymes that metabolize sulfide were not affected by SPC in this portion of the brain (Fig. 5). SQOR activity 2 h after administration of MPTP was decreased in control mice but not in mice that were pre-conditioned with H₂S before administration of MPTP (Fig. 6A). SPC also prevented the decrease in levels of sulfane sulfur, a component of persulfide and polysulfide, in the nigrostriatal region 2 h after MPTP administration (Fig. 6B). These results suggest that the protective effects of SPC, in terms of preventing MPTP-induced neurodegeneration, are associated with upregulation of SQOR and increased persulfide/polysulfide levels in the nigrostriatal region.
2.4. AAV-mediated SQOR gene transfer increased SQOR levels in substantia nigra and striatum and prevented the MPTP-induced decrease in tyrosine hydroxylase

To determine whether upregulation of SQOR is sufficient to prevent neurodegeneration after MPTP administration, we examined the effects of increased levels of SQOR, induced by administration of adeno-associated virus (AAV) encoding mouse SQOR (AAV-SQOR). We used the hSYN1 promoter to express SQOR specifically in neurons of mice. AAV-SQOR was injected into the intracerebroventricular space of newborn mice and mice were used for experiments 12 weeks after injection (Fig. 7), as previously described [31]. Twelve weeks after AAV injection, AAV-SQOR-treated mice had higher levels of SQOR in substantia nigra and striatum compared to mice that received control AAV (AAV encoding green fluorescent protein, AAV-GFP) (Fig. 8). While levels of cystathionine beta synthase (CBS) were higher in mice that received AAV-SQOR compared to AAV-GFP, levels of other enzymes that metabolize sulfide were not affected by AAV-mediated SQOR gene transfer in the nigrostriatal region (Fig. 9). Compared to control, AAV-GFP-treated mice, which were treated with saline, control mice treated with MPTP had decreased levels of tyrosine hydroxylase in the nigrostriatal region. In contrast, mice that received AAV-SQOR and were treated with MPTP had normal levels of tyrosine hydroxylase (Fig. 10A) and sulfane sulfur (Fig. 10B) in the nigrostriatal region 7 days after MPTP administration. These observations support the hypothesis that the increase in persulfide/polysulfide production by increased levels of SQOR prevents MPTP-induced neurodegeneration.

2.5. Increased levels of SQOR inhibited cell death induced by 1-methyl-4-phenylpyridinium (MPP⁺) in SH-SY5Y cells

To further examine the potential protective effect of increased SQOR levels on cell viability, we expressed SQOR in SH-SY5Y neuroblastoma cells and measured the level of lactate dehydrogenase (LDH) released into tissue culture medium after addition of MPP⁺. Transfection of a plasmid encoding SQOR was used to induce expression of SQOR in SH-SY5Y cells, which do not normally express this protein. LDH released into the supernatant was measured 24 h after the addition of MPP⁺ (5 mM). Compared to control cells treated with MPP⁺, SQOR expression decreased the release of LDH into cell culture medium (Fig. 11). In a separate set of experiments, we examined the role of SQOR in the protective effects of H₂S on the viability of SH-SY5Y cells incubated with MPP⁺. In SH-SY5Y cells without SQOR expression (control), Na₂S (a H₂S releaser) had no effect on MPP⁺-induced release of LDH (Fig. 11). However, in SH-SY5Y cells expressing SQOR, incubation with Na₂S decreased MPP⁺-induced release of LDH. These results suggest that SQOR expression protects neuronal cells from MPP⁺-induced...
Because SH-SY5Y cells do not express SQOR at baseline [31], the results also indicate that SQOR is required for the cytoprotective effects of H₂S against MPP⁺.

2.6. In the absence of SQOR, polysulfides, but not H₂S, protected SH-SY5Y cells from MPP⁺-induced cell death

Because SQOR catalyzes the conversion of sulfide to polysulfides, and because SPC or AAV-mediated SQOR overexpression prevented the decrease in sulfane sulfur after MPTP administration, we hypothesized that the beneficial effects of upregulated SQOR after MPTP administration are mediated by increased levels of polysulfides. To consider this possibility, we examined the effects of polysulfides on the viability of SH-SY5Y cells incubated with MPP⁺. Cells were treated with MPP⁺ (5 mM) for 24 h and viability was assessed by crystal violet assay [41]. Compared to control cells, treatment with Na₂S (doses between 1 and 100 μM) did not improve the viability of SH-SY5Y cells treated with MPP⁺ [42]. In contrast, treatment with Na₂S or GSSG (10 μM each) increased the viability of MPP⁺-treated SH-SY5Y cells (Fig. 12A).

To further examine the cytoprotective effects of polysulfides in a physiologically relevant context, we examined the effect of GSSSG, glutathione (GSH, a parent molecule of GSSG without a sulfane sulfur), α-lipoic acid trisulfide (1,2,3-trithiane-4-pentanoic acid, LASSS), and...
α-lipoic acid (a parent molecule of LASSS without a sulfane sulfur) on murine primary cortical neurons incubated with MPP⁺. Cells were incubated with MPP⁺ (50 μM) together with each of the above compounds for 24 h. The polysulfide compounds GSSSG and LASSS, but not the parent compounds GSH and LA, protected murine primary cortical neurons from the effects of MPP⁺ treatment (Fig. 12B and C). These results suggest that the sulfane sulfur-releasing molecules protect neurons from MPP⁺-induced cytotoxicity.

2.7. Serial administration of polysulfide prevented the reduction of tyrosine hydroxylase in the substantia nigra and striatum of MPTP-treated mice

To investigate the potential therapeutic effects of polysulfides in vivo, mice were treated with or without Na₂S₃ after administration of MPTP or saline (control). On day 0, Na₂S₃ (20 mg/kg) or saline were administered IP, immediately after injection of MPTP or saline. Between days 1–6, mice received Na₂S₃ (20 mg/kg) or saline every 12 h. We observed that administration of Na₂S₃ for 7 days prevented the MPTP-induced loss of tyrosine hydroxylase in substantia nigra and striatum (Fig. 13).

The large molecular weight of GSSSG (Mw: 644.7 DA) makes it unable to traverse the blood brain barrier after systemic administration. However, recent studies suggest that intranasal administration may permit successful passage of relatively large molecules into the central nervous system [43]. To consider the possibility that GSSSG might have a protective effect on MPTP-induced neurodegeneration when administered intranasally, GSSSG (50 mg/kg) or saline was administered immediately after administration of MPTP or saline (control) on day 0. Between days 1 and 6, mice received GSSSG at 50 mg/kg or saline every 12 h. We observed that administration of GSSSG IN prevented the MPTP-induced decrease in tyrosine hydroxylase in the nigrostriatal region (Fig. 14). Taken together, these results suggest that polysulfides...
have a robust therapeutic effect in a mouse model of PD.

3. Discussion

The current study revealed that increasing the level of polysulfides in the brain prevented neurodegenerative disease in a murine model of Parkinson’s disease. Breathing H₂S at 80 ppm for 4 h per day for 5 days before administration of MPTP prevented the subsequent development of anxiety and movement disorder. Preconditioning with H₂S also protected mice from MPTP-induced loss of tyrosine hydroxylase-containing dopaminergic neurons in substantia nigra and striatum. The beneficial effects of SPC were associated with increased levels of SQOR and sulfane sulfur in the nigrostriatal region. AAV-mediated, neuron-specific expression of SQOR in the central nervous system was sufficient to prevent MPTP-induced neurodegeneration in mice. In SH-SY5Y cells, expression of SQOR improved cell viability, despite the presence of MPP⁺. In addition, the presence of SQOR in SH-SY5Y cells was required for H₂S to exert cytoprotective effects against MPP⁺. Administration of molecules that contain sulfur (i.e. Na₂S₃, GSSSG) attenuated the reduction of tyrosine hydroxylase in the nigrostriatal region in mice treated with MPTP. Taken together, these results revealed neuroprotective effects of SQOR and polysulfides in a PD model of mice.

The potential protective role of H₂S in neurodegenerative diseases, including PD, has been a focus of intensive investigation. Previous, preclinical studies reported protective effects of exogenous H₂S donor compounds and endogenous H₂S in PD models [44–47]. Anti-oxidative, anti-apoptotic, anti-inflammatory, and pro-survival effects have been suggested to explain the cytoprotective effects of H₂S in these studies. In a previous study, we observed that chronic, intermittent inhalation of H₂S, started immediately after MPTP administration, prevented motor dysfunction and degeneration of dopaminergic neurons in the nigrostriatal region in a mouse model of PD [30]. Although we observed modest upregulation of genes encoding antioxidant proteins, including heme oxygenase-1 and glutamate-cysteine ligase, the precise mechanism of protection remained incompletely defined.

To further characterize the beneficial effects of H₂S in PD, we examined the cytoprotective effects of multiple H₂S donor compounds on SH-SY5Y cells incubated with MPP⁺. We previously found that the cytoprotective effects of H₂S donor compounds correlated with their ability to increase sulfane sulfur, but not H₂S per se, in cells and culture medium [42]. In fact, Na₂S failed to improve survival of SH-SY5Y cells incubated with MPP⁺ unless the cells also expressed SQOR. This observation suggests that SQOR is required for the beneficial effects of Na₂S.

Although protective effects of exogenous and endogenous H₂S have been studied extensively, the role of sulfide catabolism has thus far garnered little attention. We recently reported that chronic, intermittent H₂S inhalation induced robust tolerance to hypoxia and ischemic brain injury in mice. The acquired tolerance to acute hypoxia/ischemia in sulfide pre-conditioned mice was associated with increased levels of SQOR and an increased capacity to catabolize sulfide in the brain [31]. Because upregulation of SQOR increases persulfide and polysulfide levels in neurons [31], we posit that the beneficial effects of SQOR upregulation in this mouse model of PD are at least in part mediated via the effects of persulfide and polysulfide compounds. Persulfide and polysulfide species have been reported to be potent antioxidants [26]. For example, Li and colleagues showed that GSSH was 50-fold more effective than H₂S in terms of scavenging H₂O₂ at physiological pH [48]. Polysulfides, such as GSSSG can generate persulfides, such as GSSH [26, 48,49]. Therefore, administration of either persulfide or polysulfide, the latter a persulfide releasing molecule, would be expected to protect against oxidative insults caused by MPTP. However, the mechanisms responsible for the protective effects of exogenous persulfide/poly-sulfide and SQOR upregulation may not be identical. For example, persulfide/poly-sulfide can scavenge reactive oxygen species (ROS) and scavenging ROS protects dopaminergic neurons against MPP⁺ [26,50,51]. However, it is challenging to separate the effect of scavenging ROS from the other protective effects of persulfide/poly-sulfide. For another example, SQOR has been shown to mediate the therapeutic effects of H₂S via activation of adenosine monophosphate-activated protein kinase. For example, SQOR inhibition is reported to block the protective effects of H₂S on dopaminergic neurons [52].
kinase (AMPK) [52]. A number of preclinical studies have reported neuroprotective effects of AMPK activation in PD models [53,54]. Therefore, it is possible that SQOR upregulation mediates protective effects via AMPK activation. The role of AMPK activation in the protective effects of SQOR in PD remains to be examined in future studies.

Because oxidation of sulfide by SQOR donates electrons to mitochondrial ETC complex III via CoQ [35,55], it is also conceivable that upregulation of SQOR and the increased capacity to oxidize sulfide may support mitochondrial bioenergetic function and cell survival in the setting of the complex I inhibition observed in PD [35,55]. Our previous observation that Na$_2$S increases intracellular ATP levels in SH-SY5Y cells expressing SQOR, but not in SH-SY5Y cells without SQOR expression, supports this hypothesis [31].

Sulfane sulfur mediates cysteine persulfidation (or S-sulfhydration), a post-translational modification that adds a sulfur atom to a cysteine residue, potentially altering the activity of the target protein. In contrast, H$_2$S itself does not cause persulfidation [56,57]. Because cysteine persulfidation of some enzymes may prove to be beneficial in some neurodegenerative diseases [58-60], the relationship between cysteine persulfidation and the protective effect of SQOR and polysulfide remains to be elucidated. A model of the potential mechanism by which the SQOR/H$_2$S/sulfane sulfur system protects against neuronal injury is shown in Fig. 15.

We observed protective effects of trisulfide compounds in MPTP/MPP$^+$-induced cell injury. The small size of Na$_2$S$_3$ permitted us to deliver the molecule intraperitoneally, with the expectation that it would cross the blood brain barrier. Because of the large size of GSSSG, we delivered this compound intranasally and nevertheless saw protective effects. Whether GSSSG crossed the blood brain barrier after intranasal administration is uncertain. Because the sulfane sulfur of polysulfide can be transferred to thiols and persulfides to generate other polysulfides, it is possible that smaller polysulfides or persulfides (e.g. GSSH, CysSSH) are generated by GSSSG and delivered through the blood brain barrier.

There are several potential limitations of the present study. In this murine model, an exogenous chemical (MPTP) was used to acutely induce PD, which is clearly different from the chronic, slowly developing disease in humans. In addition, the behavioral tests used to study the effects of MPTP on murine anxiety and movement only crudely reflect the complex clinical symptoms of PD in humans [61].

Because MPTP and its metabolite MPP$^+$ are electrophile while persulfides are nucleophile, we cannot exclude the possibility of direct chemical reaction between MPP$^+$ and persulfides. However, we observed that trisulfides exerted cytoprotective effects at 10 $\mu$M against 5 mM of MPP$^+$ (Fig. 12A). This 500-fold difference in the concentration argues against the major role of direct chemical reaction in the beneficial effects of trisulfides.

An additional limitation is that although MPTP induces degeneration of dopaminergic neurons in the nigrostriatal region, this chemical does not induce accumulation of $\alpha$-synuclein aggregates in Lewy bodies, which are seen in patients with PD [62,63]. Additional studies will be required to examine the potential protective effects of SQOR in PD models that involve $\alpha$-synuclein aggregation.

4. Conclusion

In conclusion, in the current study, we identified SQOR as a novel therapeutic target in PD. Upregulation of SQOR induced by either SPC or
AAV-mediated gene transfer protects dopaminergic neurons in the nigrostriatal regions of the brain in a mouse model of PD. We also found that administration of polysulfides, oxidative products of sulfide catabolism by SQOR, prevents neurodegeneration of dopaminergic neurons by increasing sulfane sulfur levels. These results lay the foundation for further studies examining the role of sulfide catabolism against PD and other neurodegenerative diseases.

Funding sources

This study was supported by sponsored research agreement from Kyowa Hakko Co., Ltd. to Dr. Ichinose.

Authorship confirmation statement

FN, EM, and FI conceived of this study. FN, EM, YM, EK, ME, HH, KS, SB, KO and WJ performed experiments and data analysis. EM and FI supervised the study. FN, DB, FI, and EM wrote the manuscript with consultation from all authors.

Material and methods

Detailed description for the material and methods can be found in the supplement.

Statistical analysis

All data were presented as mean ± SEM and all individual values. An unpaired two-tailed Student’s t-test was used to compare two independent groups. Normally distributed data were analyzed with the One-way or two-way analysis of variance (ANOVA) with Tukey’s multiple comparison test. Significance was considered at the level of p < 0.05. Graphpad Prism for Windows 8.4.3 and Graphpad Prism 6 for Mac OS X (Graphpad Software Inc., La Jolla, CA, USA) was used for statistical analysis.

Declaration of competing interest

Dr. Ichinose receives research funding from Kyowa Hakko Bio Co., Ltd. Drs. Kanemaru, Ezaka, Ichinose, and Marutani are listed as inventors of patents filed by MGH related to GSSSG. Dr. Ichinose receives research funding from Kyowa Hakko Bio Co., Ltd. Drs. Kanemaru, Ezaka, Ichinose, and Marutani are listed as inventors of patents filed by MGH related to GSSSG.

Data availability

No data was used for the research described in the article.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2022.102562.

References

[1] G. Alves, E.B. Forsaa, K.F. Pedersen, M. Dreetz Gjerstad, J.P. Larsen, Epidemiology of Parkinson’s disease, J. Neurol. 255 (Suppl 5) (2008) 18–32.
[2] D.J. Moore, A.B. West, V.L. Dawson, T.M. Dawson, Molecular pathophysiology of Parkinson’s disease, Annu. Rev. Neurosci. 28 (2005) 57–87.
[3] L. Puputta, S.Y. Chung, J.W. Shin, Oxidative stress and cellular pathologies in Parkinson’s disease, Mol. Brain 10 (2017) 53.
[4] A.H. Schapira, J.M. Cooper, D. Dexter, J.B. Clark, P. Jenner, C.D. Marsden, Mitochondrial complex I deficiency in Parkinson’s disease, J. Neurochem. 54 (1990) 823–827.
[5] W.D. Parker Jr., J.K. Parks, R.H. Swerdlow, Complex I deficiency in Parkinson’s disease frontal cortex, Brain Res. 1189 (2008) 215–218.
[6] M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakub, M. Goedert, Alpha-synuclein in Lewy bodies, Nature 388 (1997) 839–840.
[7] A. Bellucci, M. Zaltieri, L. Navarria, J. Grigoletto, C. Missale, P. Spano, From α-synuclein to synaptic dysfunction: new insights into the pathophysiology of Parkinson’s disease, Brain Res. 1476 (2012) 183–202.
[8] A. Bellucci, N.B. Mercuri, A. Venneri, et al., Review: Parkinson’s disease: from synaptic loss to connectome dysfunction, Neuropsychopharmacol. Appl. Neuropsychopharmacol. 42 (2016) 77–94.
[9] P. Levitt, J.E. Pintar, X.O. Breakefield, Immunocytocchemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons, Proc. Natl. Acad. Sci. U. S. A. 79 (1982) 6385–6389.
[10] P.K. Sondalla, L.Y. Ward, R. Weinak, B. Buckley, The antiplatelet drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance, Exp. Neurol. 221 (2010) 329–334.
[11] T. Sai, K. Uchida, H. Nakayama, Biochemical evaluation of the neurotoxicity of MPTP and MPP+ in embryonic and newborn mice, J. Toxicol. Sci. 38 (2013) 445–458.
[12] J.A. Javitch, S.H. Snyder, Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP, Eur. J. Pharmacol. 168 (1984) 455–456.
[13] T. Obata, Nitric oxide and MPTP-induced hydroxyl radical generation, J. Neural. Transm. 113 (2006) 1131–1144.
[14] M. Motus, P. Roy, M.J. Guerra, E. Mendez-Alvarez, R. Soto-Otero, J.L. Labandeira-Garcia, Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism, Neuropharmacology 51 (2006) 112–120.
[15] A.H. Schapira, Mitochondrial dysfunction in Parkinson’s disease, Cell Death Differ. 14 (2007) 1261–1266.
[16] S. Sveinbjornsdottir, The clinical symptoms of Parkinson’s disease, J. Neuropsych. 139 (Suppl 1) (2016) 318–324.
[17] G.E. Meredith, D.J. Rademacher, MPTP mouse models of Parkinson’s disease: an update, J. Parkinsons Dis. 1 (2011) 9–33.
[18] M. Kashiwa, M. Kajimura, N. Goda, M. Suematsu, From O2 to H2S: a landscape of angiotensin converting enzyme in the MPTP model of parkinsonism, Neuropharmacology 51 (2006) 112–120.
[19] T. Ida, T. Sawa, H. Ibara, et al., Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling, Proc. Natl. Acad. Sci. USA 111 (2014) 7606–7611.
[20] S. Takahashi, A. Hisatune, Y. Kurauchi, T. Seki, H. Katsuki, Polysulfide protects midbrain dopaminergic neurons from MPP+ induced degeneration via enhancement of glutathione biosynthesis, J. Pharmacol. Sci. 137 (2018) 47–54.
[21] É. Doka, I. Pader, A. Biirizh, et al., A novel peroxidase detection method reveals protein peroxidase- and polysulfide-reducing functions of thioredoxin and glutathione systems, Sci. Adv. 2 (2016), e1500968.
[22] K.R. Olson, HIS and polysulfide metabolism: conventional and unconventional pathways, Biochim. Pharmacol. 149 (2017) 77–90.
[23] K. Kida, M. Yamada, K. Tokuda, et al., Inhaled hydrogen sulfide prevents neurodegeneration and movement disorder in a mouse model of Parkinson’s disease, Antioxidants Redox Signal. 15 (2010) 343–352.
[24] E. Marutani, M. Morita, S. Hirai, et al., Sulfide catabolism ameliorates hypoxic brain injury, Nat. Commun. 12 (2021) 3108.
[25] R. Yong, D.G. Searcy, Sulfide oxidation coupled to ATP synthesis in chicken liver mitochondria, Comp. Biochem. Physiol. Physiol. B Biochem. Mol. Biol. 129 (2001) 129–137.
[26] M. Goubert, M. Andriamihaja, T. Niβel, F. Blachier, F. Bouillaud, Sulfide, the first inorganic substrate for human cells, Faseb. J. 21 (2007) 1699–1706.
[27] C. Szabo, C. Ranny, K. Modis, et al., Regulation of mitochondrial bienergetic function by hydrogen sulfide. Part I. Biochemical and physiological mechanisms, Br. J. Pharmacol. 171 (2014) 2099–2122.
[28] A.P. Landry, D.P. Ballou, B. Banerjee, Hydrogen sulfide oxidation by sulfide quinone oxidoreductase, Chembiochem 22 (2021) 949–960.
[29] M.R. Jackson, S.L. Melideo, M.S. Jorns, Human sulfide:quinone oxidoreductase catalyzes the first step in hydrogen sulfide metabolism and produces a sulfane sulfur metabolite, Biochemistry 51 (2012) 6804–6815.
[30] M.R. Jackson, S.L. Melideo, M.S. Jorns, Chapter fourteen - role of human sulfide:quinone oxidoreductase are a potentially treatable cause of Leigh disease, Methods in Enzymology, Academic Press, 2015, pp. 255–270.
[31] M.W. Friedrich, A.F. Elias, A. Kuster, et al., Pathogenic variants in SQOR encoding sulfide:quinone oxidoreductase are a potentially treatable cause of Leigh disease, J. Inherit. Metab. Dis. 43 (2020) 1024–1036.
[32] E. Panarella, F. De Galía, V. Porcò, et al., Age-dependent neuropsychiatric symptoms in the Nf-κB/c-Rel knockout mouse model of Parkinson’s disease, Front. Behav. Neurosci. 16 (2022), 831664.
[33] G. Rozas, E. López-Martín, M.J. Guerra, J.L. Labandeira-García, The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism, J. Neurosci. Methods 83 (1998) 165–175.
E. Marutani, S. Kosugi, K. Tokuda, et al., A novel hydrogen sulfide-releasing N-Methyl-D-Aspartate receptor antagonist prevents ischemic neuronal death, J. Biol. Chem. 287 (2012) 32124–32135.

E. Marutani, M. Sakaguchi, W. Chen, et al., Cytoprotective effects of hydrogen sulfide-releasing N-methyl-D-aspartate receptor antagonists mediated by intracellular sulfane sulfur, Med. Chem. Commun. 5 (2014) 1577–1583.

L.R. Hanson, W.H. Frey 2nd, Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease, BMC Neurosci. 9 (Suppl 3) (2008) S5.

M. Liu, F.F. Zhao, J.J. Tang, et al., The neuroprotection of hydrogen sulfide against MPTP-induced dopaminergic neuron degeneration involves uncoupling protein 2 rather than ATP-sensitive potassium channels, Antioxidants Redox Signal. 17 (2012) 849–859.

L.F. Hu, M. Lu, C.X. Tsong, G.S. Dawe, G. Hu, J.S. Bian, Neuroprotective effects of hydrogen sulfide on Parkinson’s disease rat models, Aging Cell 9 (2010) 135–146.

R. Tabassum, N.Y. Jeong, Potential for therapeutic use of hydrogen sulfide in oxidative stress-induced neurodegenerative diseases, Int. J. Med. Sci. 16 (2019) 1386–1396.

M. Wang, J. Zhu, Y. Pan, et al., Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease, J. Neurosci. Res. 93 (2015) 487–494.

N. Wada, S. Matsugo, Revisit of the photoirradiation of α-lipoic acid—role of hydrogen sulfide produced in the reaction, Biochemistry (Rajkot, India) 1 (2021) 148–158.

S.Y. Kim, M.S. Woo, J.S. Park, H.S. Kim, Regulation of matrix metalloproteinase-9 gene expression in MPP+- or 6-OHDA-treated human neuroblastoma SK-N-BE(2)C cells, Neurochem. Int. 56 (2010) 437–442.

X. Wu, Y. Ren, Y. Wen, et al., Deacetylation of ZKSCAN3 by SIRT1 induces autophagy and protects SN4741 cells against MPP(++)-induced oxidative stress, Free Radic. Biol. Med. 181 (2022) 82–97.

J. Jia, Z. Wang, M. Zhang, et al., SQR mediates therapeutic effects of H(2)S by targeting mitochondrial electron transport to induce mitochondrial uncoupling, Sci. Adv. 6 (2020) eaaz7552.

D.W. Curry, B. Stutz, Z.B. Andrews, J.D. Elsworth, Targeting AMPK signaling as a neuroprotective strategy in Parkinson’s disease, J. Parkinsons Dis. 8 (2018) 161–181.

Z. Wen, J. Zhang, P. Tang, N. Tu, K. Wang, G. Wu, Overexpression of miR-185 inhibits autophagy and apoptosis of dopaminergic neurons by regulating the AMPK/mTOR signaling pathway in Parkinson’s disease, Mol. Med. Rep. 17 (2018) 131–137.

K.R. Olson, K.D. Straub, The role of hydrogen sulfide in evolution and the evolution of hydrogen sulfide in metabolism and signaling, Physiology 31 (2016) 60–72.

J.J. Toohey, A.J.L. Cooper, Thiosulfoxide (sulfane) sulfur: new chemistry and new regulatory roles in biology, Molecules 19 (2014) 12789–12813.

J.J. Toohey, Sulphur signaling: is the agent sulphide or sulfane? Anal. Biochem. 413 (2011) 1–7.

J.M. Hourihan, J.G. Kenna, J.D. Hayes, The neurotransmitter hydrogen sulfide induces nef2-target genes by inactivating the Keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613, Antioxidants Redox Signal. 19 (2012) 465–481.

B.D. Paul, J.J. Shiodo, R. Xu, et al., Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington’s disease, Nature 509 (2014) 96–100.

M. Kakinohana, K. Kida, S. Minamishima, et al., Delayed paraplegia after spinal cord ischemic injury requires caspase-3 activation in mice, Stroke 42 (2011) 2302–2307.

L.A. Volpicelli-Daley, K.C. Luk, T.P. Patel, et al., Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death, Neuron 72 (2011) 57–71.

K.C. Luk, V. Kehm, J. Carroll, et al., Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science 338 (2012) 949–953.